Arthritis drug repurposed to fight stem cell transplant complication

NCT ID NCT06244628

Recruiting now Disease control Sponsor: Xuzhou Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether iguratimod, a drug already used for rheumatoid arthritis, can safely and effectively treat chronic graft-versus-host disease (cGVHD) in people who have had a stem cell transplant. The study will enroll 20 adults who have persistent cGVHD despite prior treatments. Participants will take iguratimod twice daily for 4 months, and researchers will track side effects and how well the disease responds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Iguratimod (a rheumatoid arthritis drug)
What this could lead to: If it works, this could offer a new, affordable treatment option for chronic GVHD, helping control the disease with manageable side effects.
What could go wrong: This is a small, single-center trial with only 20 participants, so results may not apply broadly. The drug is being repurposed, and its effectiveness for GVHD is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CGVHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CGVHD

Contacts and locations

Locations

Kailin Xu
RECRUITING

Xuzhou, Jiangsu, 221000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.